Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience
Therapeutic Advances in Medical Oncology · 2024-01 · 16
DOI: 10.1177/17588359241258394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 12.06.2024. Verfasst von Shenyu Zhang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Life Sciences and Medicine, Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First …. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Adjuvant therapy is used to reduce the risk of hepatocellular carcinoma (HCC) recurrence and improve patient prognosis. Exploration of treatment strategies that are both efficacious and safe has been extensively performed in the recent years. Although donafenib has demonstrated good efficacy in the treatment of advanced HCC, its use as adjuvant therapy in HCC has not been reported.
Objectives
To investigate the efficacy and safety of postoperative adjuvant donafenib treatment in patients with HCC at high-risk of recurrence.
Design
Retrospective study.
Methods
A total of 196 patients with HCC at high-risk of recurrence were included in this study. Of these, 49 received adjuvant donafenib treatment, while 147 did not. Survival outcomes and incidence of adverse events (AEs) in the donafenib-treated group were compared. Inverse probability of treatment weighting (IPTW) method was used.
Results
The median follow-up duration was 21.8 months [interquartile range (IQR) 17.2–27.1]. Before IPTW, the donafenib-treated group exhibited a significantly higher 1-year recurrence-free survival (RFS) rate (83.7% versus 66.7%, p = 0.023) than the control group. Contrarily, no significant difference was observed in the 1-year overall survival (OS) rates between the two groups (97.8% versus 91.8%, p = 0.120). After IPTW, the 1-year RFS and OS rates (86.6% versus 64.8%, p = 0.004; 97.9% versus 89.5%, p = 0.043, respectively) were higher than those in the control group. Multivariate analysis revealed that postoperative adjuvant donafenib treatment was an independent protective factor for RFS. The median duration of adjuvant donafenib treatment was 13.6 (IQR, 10.7–18.1) months, with 44 patients (89.8%) experienced AEs, primarily grade 1–2 AEs.
Conclusion
Postoperative adjuvant donafenib treatment effectively reduced early recurrence among patients with HCC at high-risk of recurrence, while exhibiting favorable safety and tolerability profile. However, these findings warrant further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Life Sciences and Medicine, Department of Hepatobiliary Surgery, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, University of Science and Technology of C…
- Department of Hepatic-Biliary-Pancreatic Surgery, No. 2 People's Hospital of Fuyang City, Fuyang, Anhui, China.
- Division of Life Sciences and Medicine, Department of Medical Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China.
- Department of Hepatic-Biliary-Pancreatic Surgery, No. 2 People's Hospital of Fuyang City, 1088 Yinghe West Road, Yingzhou District, Fuyang, Anhui 236015, China.
- Anhui Provincial Clinical Research Center for Hepatobiliary Diseases, Hefei, Anhui, China.
- Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui, China.
ORCID-Profile: Shenyu Zhang, Jizhou Wang, Lianxin Liu
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, S., Yang, G., Song, R., Wang, W., Meng, F., Yin, D., Wang, J., Zhang, S., Cai, W., Liu, Y., Luo, D., Wang, J., & Liu, L. (2024). Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241258394
Vancouver
Zhang S, Yang G, Song R, Wang W, Meng F, Yin D, et al. Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience. Therapeutic Advances in Medical Oncology. 2024;16. doi:10.1177/17588359241258394
BibTeX
@article{Zhang2024,
author = {Zhang, Shenyu and Yang, Guibin and Song, Ruipeng and Wang, Wei and Meng, Fanzheng and Yin, Dalong and Wang, Jiabei and Zhang, Shugeng and Cai, Wei and Liu, Yao and Luo, Dayong and Wang, Jizhou and Liu, Lianxin},
title = {Adjuvant donafenib for hepatocellular carcinoma patients at high-risk of recurrence after radical resection: a real-world experience},
journal = {Therapeutic Advances in Medical Oncology},
year = {2024},
volume = {16},
doi = {10.1177/17588359241258394}
}
EUVIMED